POINTGUARD: First-in-Human Clinical Trial Evaluating IW-601

POINTGUARD is a randomized, blinded, placebo-controlled dose-ranging study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous single and multiple ascending doses of iW-601. The trial is expected to provide valuable efficacy & mechanistic biomarkers data.